Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

ClinicalTrials.gov ID: NCT03480763

Public ClinicalTrials.gov record NCT03480763. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed 1) to evaluate the safety, tolerability, and immunogenicity of V114 and Prevnar 13™, 2) to describe the safety of sequential administration of V114 or Prevnar 13™ followed by PNEUMOVAX™23, and 3) to evaluate the immune responses to the 15 serotypes contained in V114 when PNEUMOVAX™23 is given approximately 12 months after receipt of either V114 or Prevnar 13™ in healthy adults 50 years of age or older. There was no formal hypothesis testing.

Study identification

NCT ID
NCT03480763
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
652 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 21, 2018
Primary completion
Dec 22, 2019
Completion
Dec 22, 2019
Last update posted
Nov 1, 2021

2018 – 2019

United States locations

U.S. sites
15
U.S. states
9
U.S. cities
15
Facility City State ZIP Site status
East Valley Family Physicians ( Site 0104) Chandler Arizona 85224
Central Phoenix Medical Clinic, LLC ( Site 0125) Phoenix Arizona 85020
Encompass Clinical Research ( Site 0118) Spring Valley California 91978
Diablo Clinical Research, Inc ( Site 0132) Walnut Creek California 94598
Clinical Research of South Florida ( Site 0126) Coral Gables Florida 33134
QPS Miami Research Associates ( Site 0116) South Miami Florida 33143
Heartland Research Associates, Llc ( Site 0115) Wichita Kansas 67207
Centennial Medical Group ( Site 0109) Elkridge Maryland 21075
Rapid Medical Research, Inc. ( Site 0119) Cleveland Ohio 44122
University of Texas Medical Branch at Galveston ( Site 0127) Galveston Texas 77555-1115
Texas Center For Drug Development ( Site 0107) Houston Texas 77081
Diagnostics Research Group ( Site 0100) San Antonio Texas 78229
J Lewis Research Inc / Foothill Family Clinic ( Site 0123) Salt Lake City Utah 84109
J Lewis Research Inc/Jordan River Family Medicine ( Site 0114) South Jordan Utah 84095
Health Research of Hampton Roads, Inc. ( Site 0106) Newport News Virginia 23606

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

Recently updated Pneumococcal Infections trials

Other public records listing Pneumococcal Infections. Sorted by last update posted; newest first. Not a recommendation.

All Pneumococcal Infections trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03480763, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 1, 2021 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03480763 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →